» Articles » PMID: 33672697

Design and Synthesis of HCV-E2 Glycoprotein Epitope Mimics in Molecular Construction of Potential Synthetic Vaccines

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2021 Mar 6
PMID 33672697
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis C virus remains a global threat, despite the availability of highly effective direct-acting antiviral (DAA) drugs. With thousands of new infections annually, the need for a prophylactic vaccine is evident. However, traditional vaccine design has been unable to provide effective vaccines so far. Therefore, alternative strategies need to be investigated. In this work, a chemistry-based approach is explored towards fully synthetic peptide-based vaccines using epitope mimicry, by focusing on highly effective and conserved amino acid sequences in HCV, which, upon antibody binding, inhibit its bio-activity. Continuous and discontinuous epitope mimics were both chemically synthesized based on the HCV-E2 glycoprotein while using designed fully synthetic cyclic peptides. These cyclic epitope mimics were assembled on an orthogonally protected scaffold. The scaffolded epitope mimics have been assessed in immunization experiments to investigate the elicitation of anti-HCV-E2 glycoprotein antibodies. The neutralizing potential of the elicited antibodies was investigated, representing a first step in employing chemically synthesized epitope mimics as a novel strategy towards vaccine design.

Citing Articles

Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?.

Fu C, Yu L, Miao Y, Liu X, Yu Z, Wei M Acta Pharm Sin B. 2023; 13(2):498-516.

PMID: 36873165 PMC: 9978859. DOI: 10.1016/j.apsb.2022.07.020.


From Structural Studies to HCV Vaccine Design.

Yechezkel I, Law M, Tzarum N Viruses. 2021; 13(5).

PMID: 34064532 PMC: 8147963. DOI: 10.3390/v13050833.

References
1.
Harris J, Markl J . Keyhole limpet hemocyanin (KLH): a biomedical review. Micron. 1999; 30(6):597-623. DOI: 10.1016/s0968-4328(99)00036-0. View

2.
Mondelli M, Cerino A, Segagni L, Meola A, Cividini A, Silini E . Hypervariable region 1 of hepatitis C virus: immunological decoy or biologically relevant domain?. Antiviral Res. 2001; 52(2):153-9. DOI: 10.1016/s0166-3542(01)00180-2. View

3.
Prentoe J, Velazquez-Moctezuma R, Augestad E, Galli A, Wang R, Law M . Hypervariable region 1 and N-linked glycans of hepatitis C regulate virion neutralization by modulating envelope conformations. Proc Natl Acad Sci U S A. 2019; 116(20):10039-10047. PMC: 6525505. DOI: 10.1073/pnas.1822002116. View

4.
Clayton R, Owsianka A, Aitken J, Graham S, Bhella D, Patel A . Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol. 2002; 76(15):7672-82. PMC: 136371. DOI: 10.1128/jvi.76.15.7672-7682.2002. View

5.
Vasiliauskaite I, Owsianka A, England P, Khan A, Cole S, Bankwitz D . Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. mBio. 2017; 8(3). PMC: 5433095. DOI: 10.1128/mBio.00382-17. View